NL-OMON38399已完成不适用
PET-CT of biodistribution of rituximab in relation to therapeutic outcome and histological response of lymphoid tissue in rheumatoid arthritis patients - Rituximab PET-CT of rheumatoid arthritis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1.Men and women, * 18 years of age
- •2.Diagnosis of rheumatoid arthritis according to the ACR criteria (Arnett et al 1988)
- •3.Treatment with disease modifying anti-rheumatic drugs (DMARDS) and in addition, corticosteroids up to 10 mg daily and non-steroidal anti-inflammatory drugs (NSAIDs) is permitted, provided that there is a stable dose for at least 2 weeks. Patients should have been treated previously with at least one anti-tumour necrosis factor (anti-TNF) medication with inadequate response or intolerance. Anti-TNF should be discontinued at least 4 weeks before initiation of rituximab treatment.
- •4.Patients must be able to adhere to the study appointments and other protocol
- •requirements.
- •5. Patients must be capable of giving informed consent and the consent must have been
- •obtained prior to the study related procedures.
排除标准
- •1.Treatment with any investigational drug within the previous 3 months.
- •2.Pregnancy or breast-feeding.
- •3.Previous exposure to radioactivity (nuclear imaging) in the year preceding inclusion in this study.
研究者
相似试验
进行中（未招募）
不适用
The use of isotope-bound antibodies to visualize and subsequently treat B-cell lymphomaCD20 positive LymphomaMedDRA version: 14.0Level: PTClassification code 10003902Term: B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005474-38-BEInstitut Jules Bordet
进行中（未招募）
不适用
PET-RIMCEB:Early PET adjusted rituximab-based intensified immunochemotherapy in young poor risk DLBCL patientsA phase III studyA randomized, open-label trial comparing intensified immunochemotherapy (Rituximab[R]-MegaCHOP/R-CHOP) with intensified immunochemotherapy (R-MegaCHOP/R-CHOP) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation or observation in early PET negative young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas+A single arm trial of intensified platinum-based immunochemotherapy (R-MegaCHOP/R-Pt-based salvage regimen) followed by High Dose Therapy (BEAM) with autologous stem cell transplantation in early PET positive young poor risk patients with CD20+ Diffuse Large B-Cell Lymphomas - PET-RIMCEBPrognosis of high-risk patients with diffuse large B-cell lymphoma is still less then optimal. According to revised Int. Prognostic Index, patients with 3-5 adverse prognostic factors have only about 50% chance of survival in 4 years. In theory, there are 3 possibilities how to improve prognosis of patients with poor-risk DLBCL: intensification of induction therapy, high-dose consolidation treatment with autologous stem cell transplant or combination of both methods.EUCTR2009-016136-12-CZCzech Lymphoma Research Organization s.r.o. (CLRO)280
已完成
不适用
89Zr-rituximab PET/CT for detection of central nervous system lymphomabrain tumour1002532310029211lymphomaNL-OMON42205niversitair Medisch Centrum Utrecht12
进行中（未招募）
不适用
A new kind of scan for patients with a lymphoma in the central nervous systemcentral nervous system localized malignant lymphoma.EUCTR2015-000056-23-NLMC Utrecht
尚未招募
不适用
Determination of the pharmacokinetics of rituximab and antibodies to rituximab in patients with a B-cell CD20+ malignancy who are treated with rituximab as single agent or rituximab in combination with chemotherapy or are on maintenance therapy with rituximabNL-OMON31559Antoni van Leeuwenhoek Ziekenhuis40